激素受体阳性的绝经后乳腺癌芳香化酶抑制剂辅助治疗的时长  

The duration of treatment with adjuvant aromatase inhibitor on hormone receptor-positive postmenopausal breast cancer

作　　者：王羽 陈晰[1] 柳林[1] 梁文龙 张建国[1] WANG Yu;CHEN Xi;LIU Lin(The second affiliated hospital of Harbin medical university general surgery, Harbin 150086, China)

机构地区：[1]哈尔滨医科大学附属第二医院乳腺外科,150086

出　　处：《临床外科杂志》2018年第6期474-477,共4页Journal of Clinical Surgery

摘　　要：近年来,绝经后乳腺癌的发病率显著上升,内分泌治疗在乳腺癌综合治疗中至关重要。BIG 1-98、ATAC等经典实验确立了5年芳香化酶抑制剂(AI)治疗是激素受体阳性绝经后乳腺癌的金标准。ATLAS试验与a TTOM试验结果已经证实,10年他莫昔芬治疗效果优于5年。绝经后病人AI治疗时间是否应该延长至10年,不同的试验结果差异很大。DATA试验与MA.17R试验结果证实,应延长AI治疗的时长;IDEAL试验与NSABP B-42试验未证实延长AI治疗更有效。对诸多试验进行分析后总结出,是否需要延长AI治疗时间,应结合病人各方面因素进行综合分析。In recent years,the incidence of postmenopausal breast cancer has significantly increased. Endocrine therapy is critical to the treatment of comprehensive breast cancer. The BIG 1-98 trial,ATAC trial and other classic trials have established golden standard for the treatment for HR ＋ postmenopausal breast cancer,in which the duration of aromatase inhibitor（ AI） was 5-years. While ATLAS trial and a TTOM trial have confirmed that the effect of treating with tamoxifen for 10 years was better than 5 years.Thus the duration of treatment with AI was controversial. The DATA trial and the MA. 17 R trial have confirmed that the duration of AI treatment should be prolonged,while the IDEAL trial and the NSABP B-42 trial haven＇t shown that prolonging the duration of AI treatment was more effective. Here is a review on the duration of AI treatment based on various trials.

关 键 词：绝经后 激素受体阳性乳腺癌 芳香化酶抑制剂 治疗时长 无病生存率 

分 类 号：R737.9[医药卫生—肿瘤]